{"entity":{"id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","aka":[],"tldr":"A phase 2/3 trial of Futibatinib, Fulvestrant in metastatic cancer, run by Taiho Oncology, Inc., active and no longer recruiting.","summary":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. is a phase 2/3 interventional study registered as NCT06506955 by Taiho Oncology, Inc., with 15 participants planned, started 2024-10-01 and due to reach its primary completion in 2027-04. Interventions recorded: futibatinib, futibatinib, fulvestrant. Conditions listed: Advanced/Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06506955","url":"https://clinicaltrials.gov/study/NCT06506955"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["futibatinib","fulvestrant"],"companies":["taiho-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06506955","phase":"2/3","setting":"An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study","sponsor":"Taiho Oncology, Inc.","enrolled":15,"outcomes":[]},"route":"/trials/nct06506955/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/"}],"company":[{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/"}]}}